title: Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.
abstract: OBJECTIVE
  Progression-free survival (PFS) in metastatic castration-resistant prostate cancer (mCRPC) trials has been inconsistently defined and poorly associated with overall survival (OS). A reproducible quantitative definition of radiographic PFS (rPFS) was tested for association with a coprimary end point of OS in a randomized trial of abiraterone in patients with mCRPC.
  
  
  METHODS
  rPFS was defined as ≥ two new lesions on an 8-week bone scan plus two additional lesions on a confirmatory scan, ≥ two new confirmed lesions on any scan ≥ 12 weeks after random assignment, and/or progression in nodes or viscera on cross-sectional imaging, or death. rPFS was assessed by independent review at 15% of deaths and by investigator review at 15% and 40% of deaths. rPFS and OS association was evaluated by Spearman's correlation.
  
  
  RESULTS
  A total of 1,088 patients were randomly assigned to abiraterone plus prednisone or prednisone alone. At first interim analysis, the hazard ratio (HR) by independent review was 0.43 (95% CI, 0.35 to 0.52; P < .001; abiraterone plus prednisone: median rPFS, not estimable; prednisone: median rPFS, 8.3 months). Similar HRs were obtained by investigator review at the first two interim analyses (HR, 0.49; 95% CI, 0.41 to 0.60; P < .001 and HR, 0.53; 95% CI, 0.45 to 0.62; P < .001, respectively), validating the imaging data assay used. Spearman's correlation coefficient between rPFS and OS was 0.72.
  
  
  CONCLUSIONS
  rPFS was highly consistent and highly associated with OS, providing initial prospective evidence on further developing rPFS as an intermediate end point in mCRPC trials.
authors.affiliation: Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium. morrism@mskcc.org.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Morris
authors.affiliation: Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium.
authors.forename: Arturo
authors.initials: A
authors.lastname: Molina
authors.affiliation: Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium.
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Small
authors.affiliation: Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium.
authors.forename: Johann S
authors.initials: JS
authors.lastname: de Bono
authors.affiliation: Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium.
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Logothetis
authors.affiliation: Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium.
authors.forename: Karim
authors.initials: K
authors.lastname: Fizazi
authors.affiliation: Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium.
authors.forename: Paul
authors.initials: P
authors.lastname: de Souza
authors.affiliation: Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium.
authors.forename: Philip W
authors.initials: PW
authors.lastname: Kantoff
authors.affiliation: Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium.
authors.forename: Celestia S
authors.initials: CS
authors.lastname: Higano
authors.affiliation: Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium.
authors.forename: Jinhui
authors.initials: J
authors.lastname: Li
authors.affiliation: Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium.
authors.forename: Thian
authors.initials: T
authors.lastname: Kheoh
authors.affiliation: Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium.
authors.forename: Steven M
authors.initials: SM
authors.lastname: Larson
authors.affiliation: Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium.
authors.forename: Shannon L
authors.initials: SL
authors.lastname: Matheny
authors.affiliation: Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium.
authors.forename: Vahid
authors.initials: V
authors.lastname: Naini
authors.affiliation: Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium.
authors.forename: Tomasz
authors.initials: T
authors.lastname: Burzykowski
authors.affiliation: Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium.
authors.forename: Thomas W
authors.initials: TW
authors.lastname: Griffin
authors.affiliation: Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium.
authors.forename: Howard I
authors.initials: HI
authors.lastname: Scher
authors.affiliation: Michael J. Morris, Steven M. Larson, and Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Arturo Molina, Thian Kheoh, Shannon L. Matheny, Vahid Naini, and Thomas W. Griffin, Janssen Research & Development, Los Angeles; Eric J. Small and Charles J. Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; Johann S. de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom; Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia; Philip W. Kantoff, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Celestia S. Higano, University of Washington, Seattle, WA; Jinhui Li, Janssen Research & Development, Raritan, NJ; and Tomasz Burzykowski, International Drug Development Institute, Louvain-la-Neuve, Belgium.
authors.forename: Charles J
authors.initials: CJ
authors.lastname: Ryan
mesh_terms: D000069501:Abiraterone Acetate; D000736:Androstenes / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D018572:Disease-Free Survival; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D064129:Prostatic Neoplasms, Castration-Resistant / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000473:pathology; D011859:Radiography; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000736:Androstenes; D014408:Biomarkers, Tumor; D000069501:Abiraterone Acetate; D011241:Prednisone